Healthcare Industry News: American Pharmaceutical Partners
News Release - September 8, 2006
Abraxis BioScience Names Leadership Team for Its Abraxis Pharmaceutical Products DivisionAppointment of President and Chief Operating Officer of APP Solidifies Management Structure of Hospital-Based Division
New Corporate General Counsel Also Named for Abraxis BioScience
LOS ANGELES--(HSMN NewsFeed)--Sept. 8, 2006--Abraxis BioScience, Inc. (NASDAQ:ABBI ), an integrated, global biopharmaceutical company, today announced that Thomas H. Silberg, who had previously served as the company's executive vice president, commercial operations & operational excellence, has now been named as president of Abraxis Pharmaceutical Products (APP), and Frank Harmon, who has served as executive vice president, global operations, will now report to Silberg and assume the role of chief operating officer for the APP division. It was also announced that Richard E. Maroun, the company's chief administrative officer, will add to his current responsibilities and assume the role of general counsel and corporate secretary. Maroun, Silberg and Harmon will continue to serve on the Executive Committee for Abraxis BioScience.
Maroun replaces John F. Weidenbruch as general counsel and corporate secretary. Maroun, prior to the merger of American BioScience, Inc. (ABI) and American Pharmaceutical Partners, Inc., served as general counsel and vice president of corporate development of ABI. Weidenbruch has chosen to accept a position as executive vice president and general counsel at Idenix Pharmaceuticals, Inc. based in Cambridge, Massachusetts.
"I would like to welcome Rick, Tom and Frank to their new roles. Rick has been a valuable member of this team and his continued leadership in this broader role will only serve to strengthen the foundation of the company. Both Tom and Frank have been playing vital roles in the APP division over the last few months and already have demonstrated their capabilities in taking on their new responsibilities. I have every confidence they will continue to show the same dedication and devotion to growing the business moving forward," said Patrick Soon-Shiong, M.D., chairman and chief executive officer of Abraxis BioScience. "Finally, this last year has been an incredibly busy time for the company and I can't thank John enough for his dedication to the company. We wish him the best of luck as he begins this new chapter in his career."
Each of these appointments are subject to approval from the Board of Directors.
About Abraxis BioScience, Inc.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANEŽ, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq National Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.
Source: Abraxis BioScience
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.